title: [Clinical Analysis of 153 Cases of Refractory/Relapsed Diffuse Large B-cell Lymphoma].
abstract: OBJECTIVE
  To analyze the clinical features and treatment methods of refractory/relapsed diffuse large B cell lymphoma (DLBCL) patients, and to explore the curative effect and the main factors affecting prognosis.
  
  
  METHODS
  Clinical data of 1043 cases of DLBCL in our hospital from January 2008 to April 2016 were retrospectively analyzed, then the clinical data of 153 patients with refractory/relapsed lymphoma were selected and analyzed for determing the relationship of the related factors with therapeutic effect and prognosis. Treatment methods include chemotherapy alone and chemotherapy combined with radio-therapy, the first line regimen was CHOP or R-CHOP program, the salvage regimens are ICE, Hyper CVAD or EPOCH, etc. The median age of these 153 patients was 50 years old, the ratio of male and female was 1.59:1.
  
  
  RESULTS
  4 cases were not treated in 153 patients, 6 cases (4.03%) of 149 patients have been treated and achieved complete remission(CR), 18 cases (12.08%) achieved partial remission(PR), and the total response rate was 16.1%. Single factor analysis showed that the patients' serum LDH values, IPI score, bulky, extra-node involvement, bone marrow infiltration and the salvage regimen all could influence the survival rate, with statistically significantce (P<0.05).
  
  
  CONCLUSIONS
  Refractory/relapsed DLBCL mainly occurs in the middle-aged and male, the serum LDH value, IPI score, bulky and scope of lesions are mainly factors influencing the prognosis of refractory/relapsed DLBCL patients.
authors.affiliation: Department of Geriatric Hematology,Chinese PLA General Hospital,Beijing 100853,China.
authors.forename: Dan-Dan
authors.initials: DD
authors.lastname: Zou
authors.affiliation: Department of Geriatric Hematology,Chinese PLA General Hospital,Beijing 100853,China.
authors.forename: Bo
authors.initials: B
authors.lastname: Guo
authors.affiliation: The First Outpatient Department of the Department of Logistics Support, Central Military Commission, Beijing 100853, China.
authors.forename: Peng
authors.initials: P
authors.lastname: Yin
authors.affiliation: The First Outpatient Department of the Department of Logistics Support, Central Military Commission, Beijing 100853, China.
authors.forename: Ye
authors.initials: Y
authors.lastname: Tian
authors.affiliation: Department of Geriatric Hematology,Chinese PLA General Hospital,Beijing 100853,China. E-mail: bjzhuhl301@vip.sina.com.
authors.forename: Hong-Li
authors.initials: HL
authors.lastname: Zhu
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols; D005260:Female; D006801:Humans; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D012074:Remission Induction; D012189:Retrospective Studies; D000069283:Rituximab; D016879:Salvage Therapy; D016896:Treatment Outcome
chemical_list: D000069283:Rituximab